Rockville, MD — The **Association for Research in Vision and Ophthalmology (ARVO)** launched its
third journal
,
Translational Vision Science & Technology
(
TVST
)
, with an open call for manuscript submissions this month.
TVST
is an online only, peer-reviewed journal emphasizing multidisciplinary research that bridges the gap between basic research and clinical care.

The new journal, to be published in English, will accept manuscripts by scientists and clinicians with diverse backgrounds ranging from basic chemistry to ophthalmic surgery, bringing together research that, until now, often has been published in journals other than those directly related to ophthalmology.

"*TVST's* focus on translational research is unique as is the attempt to bring innovators and facilitators together through a periodical that has extremely high standards," said *TVST's* edi
tor-in-chief, Marco Zarbin, MD, PhD, FARVO. "Our goal is to create a venue in which these innovations can be subject to rigorous peer review and, having been strengthened by that process, make their way into the public domain and directly to the attention of an appropriate audience of fellow innovators and potential scientific and business partners."

Zarbin is the chair of the Institute of Ophthalmology and Visual Science, New Jersey Medical School and chief of ophthalmology at University Hospital in Newark, N.J. He is a professor of ophthalmology and neuroscience and holds the Alfonse A. Cinotti, MD/Lions Eye Research Chair in the Department of Ophthalmology. In addition to his current role with *TVST,* Zarbin previously served as an associate editor of ARVO's
Investigative Ophthalmology and Visual Science (IOVS)
journal.

Appointed by ARVO Board of Trustees, Zarbin is joined by a team of highly-qualified associate

editors and editorial board members from across the globe in publishing the new journal, which will cover a broad spectrum of work, including:

- Applications of stem cell technology for regenerative medicine
- Development of new animal models of human diseases
- Tissue bioengineering
- Chemical engineering to improve virus-based gene delivery
- Nanotechnology for drug delivery
- Design and synthesis of artificial extracellular matrices
- Development of a true microsurgical operating environment
- Refining data analysis algorithms to improve *in vivo* imaging technology
- Results of Phase 1 clinical trials
- Reverse translational ("bench to bedside") research

“We are confident that *TVST* will be an excellent complement to ARVO’s other peer-reviewed journals — *IOVS* and *Journal of Vision* — by expanding our knowledge of cutting-edge research leading to novel treatment of vision-threatening diseases,” said ARVO President Jeffrey H. Boatright, PhD, FARVO.

The inaugural issue of *TVST* is planned for release this spring. For information on the manuscript submission process, visit www.tvstjournal.org .

# # #

The **Association for Research in Vision and Ophthalmology** (ARVO) is the largest eye and vision research organization in the world. Members include more than 12,500 eye and vision researchers from over 80 countries. ARVO encourages and assists research, training, publication and knowledge-sharing in vision and ophthalmology.